Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M05D1 in Advanced or Metastatic Solid Tumors
NCT07021066Phase 1Active, not recruiting
- Sponsor
- SystImmune Inc.
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M05D1 in solid tumor, gastric adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC) and 2 more, sponsored by SystImmune Inc. Primary endpoints: Dose-limiting toxicities at 1 year, Serious Adverse Events and treatment-emergent adverse events at 1 year and 5 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
BL-M05D1
03
Conditions
solid tumorgastric adenocarcinomapancreatic ductal adenocarcinoma (PDAC)esophageal adenocarcinoma (EAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07021066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021066.